<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02457910</url>
  </required_header>
  <id_info>
    <org_study_id>VICC BRE 1374</org_study_id>
    <secondary_id>NCI-2015-00795</secondary_id>
    <secondary_id>GO28972</secondary_id>
    <secondary_id>TBCRC 032</secondary_id>
    <secondary_id>VICC BRE 1374</secondary_id>
    <secondary_id>P30CA068485</secondary_id>
    <nct_id>NCT02457910</nct_id>
  </id_info>
  <brief_title>Taselisib and Enzalutamide in Treating Patients With Androgen Receptor Positive Triple-Negative Metastatic Breast Cancer</brief_title>
  <official_title>A Phase Ib/II Trial of Taselisib (GDC-0032), a PI3K Inhibitor, in Combination With Enzalutamide in Patients With Androgen Receptor Positive Triple Negative Metastatic Breast Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Vanderbilt-Ingram Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>Translational Breast Cancer Research Consortium</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Conquer Cancer Foundation</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Genentech, Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Vanderbilt-Ingram Cancer Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This partially randomized phase Ib/II trial studies the side effects and best dose of
      taselisib when given together with enzalutamide and to see how well they work in treating
      patients with androgen receptor positive triple-negative breast cancer that has spread to
      other places in the body. Taselisib is a PI3K inhibitor. The PI3K pathway is involved is
      cancer growth. Androgen may cause the growth of tumor cells. Enzalutamide may stop the growth
      of tumor cells by blocking the androgen receptor from working. Giving taselisib with
      enzalutamide may be a better treatment for patients with breast cancer.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PRIMARY OBJECTIVES:

      I. To determine the safety and tolerability of taselisib given in combination with
      enzalutamide: Assessment of dose limiting toxicities (DLTs) during the first 4 weeks of
      treatment (cycle 1). (Phase Ib) II. To determine the safety and tolerability of taselisib
      given in combination with enzalutamide: Determination of the maximally tolerated dose (MTD)
      of taselisib given in combination with enzalutamide. (Phase Ib) III. To evaluate the
      efficacy, as measured by clinical benefit rate (CBR), of enzalutamide + taselisib in patients
      with androgen receptor positive (AR+) triple negative (TN) metastatic breast cancer (MBC).
      (Phase II)

      SECONDARY OBJECTIVES:

      I. To determine the progression free survival (PFS) of enzalutamide + taselisib in patients
      with AR+ TN MBC.

      II. To assess the pharmacokinetics (PKs) of taselisib and enzalutamide in patients with AR+
      TN MBC.

      TERTIARY OBJECTIVES:

      I. To explore predictors of biomarker response and mechanisms of resistance based on
      exploratory analysis of tumor tissue obtained through biopsies.

      II. Levels of phosphatase and tensin homolog (PTEN) expression by immunohistochemistry (IHC)
      and quantitative real-time polymerase chain reaction (qPCR).

      III. Presence of mutations in the phosphatidylinositol-4,5-bisphosphate 3-kinase, catalytic
      subunit alpha (PIK3CA) gene.

      IV. Human epidermal growth factor receptor 2 (HER2) (IHC, fluorescence in situ hybridization
      [FISH]) and estrogen receptor (ER)/progesterone receptor (PR) levels (IHC) in tumor biopsy
      from a metastatic site.

      V. Levels of mitogen-activated protein kinase kinase (MEK) activity measured by
      phosphorylated extracellular-signal-regulated kinases (p-ERK1/2) (IHC) and phosphorylated
      p-ribosomal protein S6 (S6) (S235/236 and S240/244) at baseline and upon progression of
      disease.

      VI. Levels of phosphorylated v-akt murine thymoma viral oncogene homolog 1 (p-AKT) (IHC) at
      baseline and upon progression of disease.

      VII. Gene expression profiling to assign a triple negative subtype. VIII. Whole exome
      deoxyribonucleic acid (DNA)-sequencing (seq) on DNA isolated at baseline and upon
      progression.

      IX. Plasma for circulating tumor DNA (ctDNA) analysis to assess PIK3CA mutation status in
      response and resistance.

      X. To assess the predictive effects of PIK3CA mutations and PTEN loss on PFS and CBR.

      XI. To evaluate the ability of multi-parametric magnetic resonance imaging (MRI) performed
      early in therapy to predict both biological and clinical response.

      OUTLINE: This is a phase Ib, dose-escalation study of taselisib followed by a randomized
      phase II study.

      PHASE IB: Patients receive taselisib orally (PO) once daily (QD) on days 1-28 and
      enzalutamide PO QD on days 9-28 of course 1 and days 1-28 of subsequent courses. Courses
      repeat every 28 days in the absence of disease progression or unacceptable toxicity.

      PHASE II: Patients are randomized to 1 of 2 treatment arms.

      ARM I: Patients receive taselisib PO QD and enzalutamide as in Phase Ib. Courses repeat every
      28 days in the absence of disease progression or unacceptable toxicity. Patients experiencing
      unacceptable toxicity due to enzalutamide may continue to receive taselisib.

      ARM II: Patients receive enzalutamide PO QD on days 1-28. Courses repeat every 28 days in the
      absence of disease progression or unacceptable toxicity. Upon disease progression, patients
      may crossover to Arm I.

      After completion of study treatment, patients are followed up for 30 days and then every 3
      months for 3 years.
    </textblock>
  </detailed_description>
  <overall_status>Suspended</overall_status>
  <why_stopped>
    Interim analysis
  </why_stopped>
  <start_date>June 2015</start_date>
  <completion_date type="Anticipated">December 2021</completion_date>
  <primary_completion_date type="Anticipated">December 2019</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Clinical Benefit Rate (CBR) - Phase II</measure>
    <time_frame>At 16 weeks</time_frame>
    <description>CBR is defined as the proportion of patients with a best response of complete response (CR), partial response (PR), or (SD) stable disease. This will be studied using a Simon two-stage design.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Maximum Tolerated Dose (MTD) - Phase I</measure>
    <time_frame>4 weeks</time_frame>
    <description>defined as the highest dose tested in which a dose limiting toxicity is experienced by 0 out of 3 or 1 out of 6 patients among the dose levels. Dose limiting toxicity will be graded according to the National Cancer Institute CTCAE version 4.0.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall Progression-Free Survival (PFS)</measure>
    <time_frame>Time from course 1, day 1 until objective tumor progression, assessed up to 3 years</time_frame>
    <description>The overall PFS data for the patients at the dose recommended for phase II will be estimated using the Kaplan-Meier method with 95% confidence intervals.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall response rate (ORR)</measure>
    <time_frame>Up to 3 years</time_frame>
    <description>The ORR and corresponding 95% confidence intervals will be calculated at the dose recommended for phase II.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cmax, the peak plasma concentration of taselisib after administration of taselisib</measure>
    <time_frame>0-4 hours pre-dose and 1, 3, and 6 hours post-administration (course 1, day 8 of phase Ib)</time_frame>
    <description>Plasma samples may be used for exploratory analysis to evaluate potential taselisib-related metabolites and/or exploratory biomarker development.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cmax, the peak plasma concentration of taselisib and enzalutamide after administration of both drugs</measure>
    <time_frame>0-4 hours (hrs) pre-dose, 1, 3, and 6 hrs post-administration (course 2, day 15); 0-4 hrs pre-dose, 3 hrs post-administration (course 4, day 1), 0-4 hrs pre-dose, 2-4 hrs post administration (course 1, day 8, course 2 day 15, course 4 day 1 of phase II)</time_frame>
    <description>Plasma samples may be used for exploratory analysis to evaluate potential taselisib-related metabolites and/or exploratory biomarker development.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Changes in biopsy analysis (including proliferation, mitosis, apoptosis, genomic instability, levels of PTEN, PI3KCA mutational analysis, HER2 and ER/PR levels, levels of MEK and AKT)</measure>
    <time_frame>Baseline up to 3 years</time_frame>
    <description>Biopsy analysis will be performed in conjunction with the Pathology and Tissue Informatics Core to assess baseline, therapy-induced changes and status upon progression.</description>
  </other_outcome>
  <other_outcome>
    <measure>Changes in RNA-seq analysis</measure>
    <time_frame>Baseline up to 3 years</time_frame>
    <description>RNA-seq will be performed on all biopsies to assign a triple negative subtype and define mutations present in the tumors both at baseline and upon progression of the disease.</description>
  </other_outcome>
  <other_outcome>
    <measure>Treatment-induced changes in gene expression analysis</measure>
    <time_frame>Baseline to up to 10 days of treatment</time_frame>
    <description>Ribonucleic acid (RNA)-seq will be performed on all biopsies to determine baseline and treatment-induced changes in gene expression after 5-10 days of therapy.</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">73</enrollment>
  <condition>Estrogen Receptor Negative</condition>
  <condition>Estrogen Receptor Positive</condition>
  <condition>HER2/Neu Negative</condition>
  <condition>Progesterone Receptor Negative</condition>
  <condition>Progesterone Receptor Positive</condition>
  <condition>Stage IV Breast Cancer</condition>
  <condition>Triple-Negative Breast Carcinoma</condition>
  <arm_group>
    <arm_group_label>Arm I (taselisib, enzalutamide)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive taselisib PO QD on days 1-28 and enzalutamide PO QD on days 9-28 of course 1 and days 1-28 of subsequent courses. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients experiencing unacceptable toxicity due to enzalutamide may continue to receive taselisib.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm II (enzalutamide)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients receive enzalutamide PO QD on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity. Upon disease progression, patients may crossover to Arm I.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Biomarker Analysis</intervention_name>
    <description>Correlative studies</description>
    <arm_group_label>Arm I (taselisib, enzalutamide)</arm_group_label>
    <arm_group_label>Arm II (enzalutamide)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Enzalutamide</intervention_name>
    <description>Given PO</description>
    <arm_group_label>Arm I (taselisib, enzalutamide)</arm_group_label>
    <arm_group_label>Arm II (enzalutamide)</arm_group_label>
    <other_name>MDV3100</other_name>
    <other_name>Xtandi</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Pharmacological Study</intervention_name>
    <description>Correlative studies</description>
    <arm_group_label>Arm I (taselisib, enzalutamide)</arm_group_label>
    <arm_group_label>Arm II (enzalutamide)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Taselisib</intervention_name>
    <description>Given PO</description>
    <arm_group_label>Arm I (taselisib, enzalutamide)</arm_group_label>
    <arm_group_label>Arm II (enzalutamide)</arm_group_label>
    <other_name>GDC-0032</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients must provide informed written consent

          -  Eastern Cooperative Oncology Group (ECOG) performance status 0-1

          -  Clinical stage IV invasive mammary carcinoma

          -  For phase 1b: HER2 negative, as defined for phase II; any ER/PR (negative or positive)
             can be enrolled in the phase 1b portion

          -  For phase II: ER negative (defined as expression of ER in =&lt; 1% cells), PR negative
             (defined as expression of PR in =&lt; 1% cells), HER2 negative (acceptable methods of
             HER2 analysis include IHC [0, 1+], fluorescence in situ hybridization [FISH] with
             HER2/centromere on chromosome 17 [CEN17] ratio &lt; 2, and/or chromogenic in situ
             hybridization [CISH] with HER2/CEN-17 ratio &lt; 2), as previously documented by
             histological analysis

          -  Androgen receptor positivity, defined as &gt;= 10% of tumor cell nuclei with
             immunoreactivity for AR on central review at Vanderbilt

          -  Measurable or bone-only evaluable disease; measurable disease is defined as at least
             one lesion that can be accurately measured in at least one dimension by Response
             Evaluation Criteria in Solid Tumors (RECIST) criteria 1.1, with radiologic scans
             within 21 days of day 1, cycle 1

          -  Any number of prior therapies as long as patients have adequate performance status and
             meet all other eligibility criteria

          -  Prior treatment with anti-androgens other than enzalutamide is acceptable

          -  Phase 1b only: Formalin-fixed paraffin embedded blocks (FFPB) or fresh frozen tissue
             from the original diagnosis or the metastatic setting should be located; tissue must
             be submitted with 3 weeks of study initiation

          -  Phase II only: Biopsy of a metastatic lesion in patients with reasonably accessible
             metastatic lesions (chest wall, skin, subcutaneous tissue, lymph nodes, skin, breast,
             bones, lung, and liver metastases); if a reasonably accessible metastatic lesion is
             not available, the patient may go on study provided that archived tissue is available;
             however, if a reasonably accessible site is available for biopsy, the patient must
             agree to biopsy; any patients not undergoing biopsy must be approved for study
             enrollment by the Protocol Chair; biopsies may be done with local anesthesia or
             intravenous conscious sedation, according to institutional guidelines; if a biopsy
             requires general anesthesia, then it is only allowed if acquisition of tissue is
             clinically indicated, and excess tissue may be collected for research purposes;
             patients without sites available for biopsy must have available tissue (archived
             formalin-fixed paraffin embedded blocks [FFPB] or fresh frozen tissue from original
             diagnosis or metastatic setting) for correlative studies; tissue needs to be located
             and available at the time of registration (tissue needs to be submitted within 3 weeks
             of study initiation)

          -  Patients must have adequate hematologic, hepatic, and renal function. All tests must
             be obtained within 28 days of starting treatment. Labs are to be repeated on C1D1 and
             must still meet eligibility. These include:

          -  Absolute neutrophil count (ANC) &gt;= 1500/mm^3

          -  Platelet count &gt;= 75,000/mm^3

          -  Hemoglobin (HgB) &gt;= 9 g/dL

          -  Creatinine =&lt; 1.5 X upper limits of normal (ULN)

          -  INR â‰¤2

          -  Total serum bilirubin =&lt; 1.5 x ULN (in patients with known Gilbert syndrome, a total
             bilirubin =&lt; 3.0 x ULN, with direct bilirubin =&lt; 1.5 x ULN)

          -  Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =&lt; 3 x ULN (or =&lt;
             5.0 x ULN if hepatic metastases are present)

          -  For patients without known type II diabetes, the following is required at screening:

               -  Fasting plasma glucose =&lt; 160 mg/dL (7.49 mmol/L) and glycosylated hemoglobin
                  (HbA1c) &lt; 7.5 % or International Federation of Clinical Chemistry (IFCC) &lt; 53
                  mmol/mol

          -  For patients with type II diabetes receiving only oral anti-hyperglycemic therapy
             (patients receiving insulin are not eligible), the following are required at
             screening:

               -  HbA1c &lt; 8.5 % or IFCC &lt; 69.4 mmol/mol

               -  Stable regimen of oral anti-hyperglycemic therapy without insulin usage for at
                  least 3 weeks prior to first study treatment

               -  Fasting plasma glucose levels =&lt; 160 mg/dL (8.88 mmol/L) and no hypoglycemia
                  (blood sugar [BS] &lt; 60) during home monitoring for at least 1 week prior to study
                  entry

          -  Patients must be able to swallow and retain oral medication

          -  For patients who are not postmenopausal or surgically sterile (absence of ovaries
             and/or uterus), agreement to remain abstinent or to use two adequate methods of
             contraception (e.g., condoms, diaphragm, vasectomy/vasectomized partner, tubal
             ligation), during the treatment period and for at least 30 days after the last dose of
             study treatment or 3 months after discontinuation of taselisib and/or enzalutamide,
             whichever is longer; hormone based oral contraceptives are not allowed on study;
             postmenopausal is defined as:

               -  Age &gt;= 60 years

               -  Age =&lt; 60 years and amenorrheic for 12 months in the absence of chemotherapy,
                  tamoxifen, toremifene, or ovarian suppression; or follicle stimulating hormone
                  and estradiol in the postmenopausal range

          -  Patients may have received radiation therapy to painful bone metastases or areas of
             impending bone fracture as long as radiation therapy is completed &gt;= 2 weeks prior to
             day 1 of cycle 1 of treatment; patients who have received prior radiotherapy must have
             recovered from toxicity (=&lt; grade 1) induced by this treatment; baseline radiologic
             scans must be obtained after completion of radiation

          -  Patients must complete all screening assessments

        Exclusion Criteria:

          -  Any kind of malabsorption syndrome significantly affecting gastrointestinal function,
             including history of Crohn's disease or inflammatory bowel disease

          -  Concurrent anti-cancer therapy (chemotherapy, radiation therapy, surgery,
             immunotherapy, hormonal therapy, biologic therapy) other than the ones specified in
             the protocol; patients must have discontinued the above cancer therapies for 1 week
             prior to the first dose of study medication, as well as recovered to baseline from
             toxicity induced by previous treatments; any investigational drugs should be
             discontinued 2 weeks prior to the first dose of study medication and radiotherapy must
             have been completed &gt;= 2 weeks prior to initiation of study drug (cycle 1, day 1)

          -  Prior use of PI3K or Akt inhibitors in the metastatic setting for the treatment of
             cancer; these include, but are not limited to: taselisib, GDC-0941, GDC-0980, BEZ235,
             BKM120, LY294002, PIK-75, TGX-221, XL147, XL765, SF1126, PX-866, D-87503, D-106669,
             GSK615, CAL101; patients who have received PI3K/Akt inhibitors previously for &lt; 4
             weeks will be eligible

          -  Prior treatment with enzalutamide

          -  Current or previously treated brain metastasis or active leptomeningeal disease; head
             imaging is required during screening in all patients to exclude the presence of
             central nervous system (CNS) metastatic disease

          -  History of seizure or any condition that may predispose to seizure; history of loss of
             consciousness or transient ischemic attack within 12 months before day 1

          -  Pregnant or lactating women

          -  Insulin-dependent diabetes; patients with type II diabetes must meet the inclusion
             criteria outlined above

          -  Uncontrolled intercurrent illness including, but not limited to:

               -  Ongoing or active infection requiring parenteral antibiotics

               -  Impairment of lung function (chronic obstructive pulmonary disease [COPD] &gt; grade
                  2, lung conditions requiring oxygen therapy) or current dyspnea at rest

               -  Symptomatic congestive heart failure (class III or IV of the New York Heart
                  Association classification for heart disease)

               -  Known left ventricular ejection fraction (LVEF) &lt; 50%

               -  Unstable angina pectoris, angioplasty, stenting, or myocardial infarction within
                  6 months

               -  Uncontrolled hypertension (systolic blood pressure &gt; 160 mm Hg or diastolic blood
                  pressure &gt; 100 mm Hg, found on two consecutive measurements separated by a 1 or
                  2-week period despite adequate medical support)

               -  Clinically significant cardiac arrhythmia (multifocal premature ventricular
                  contractions, bigeminy, trigeminy, ventricular tachycardia that is symptomatic or
                  requires treatment [National Cancer Institute-Common Terminology Criteria for
                  Adverse Events, version 4.0, grade 3])

               -  Corrected QT using the Fridericia correction formula (QTcF) &gt;= 480 msec on
                  screening electrocardiogram (EKG)

               -  Known history of QT/correct QT (QTc) prolongation or Torsades de Pointes (TdP)

               -  ST depression or elevation of &gt;= 1.5 mm in 2 or more leads

               -  Diarrhea of any cause &gt;= Common Terminology Criteria for Adverse Events (CTCAE)
                  grade 2

               -  Active autoimmune disease that is not controlled by nonsteroidal or steroidal (&lt;
                  10 mg of prednisone per day) anti-inflammatory drugs or active inflammatory
                  disease, including small or large intestine inflammation such as active Crohn's
                  disease or ulcerative colitis, which requires immunosuppressive therapy

               -  Psychiatric illness/social situations that would compromise patient safety or
                  limit compliance with study requirements including maintenance of a
                  compliance/pill diary

               -  Known history of chronic liver disease including cirrhosis, current alcohol
                  abuse, or infection with hepatitis B virus or hepatitis C virus (active or
                  carrier) or renal failure

               -  Known history of chronic pancreatitis

               -  Conditions that affect lymphocyte counts, such as human immunodeficiency virus
                  (HIV) infection or immunosuppressive therapy

          -  Use of prohibited drugs
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Vandana Abramson, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Vanderbilt University/Ingram Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Alabama, Birmingham</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35249</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Georgetown University</name>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <zip>20007</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Chicago</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60637</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Indiana University</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>47405</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>John Hopkins University</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21218</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dana Farber Cancer Institute</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Michigan</name>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mayo Clinic</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55905</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of North Carolina</name>
      <address>
        <city>Chapel Hill</city>
        <state>North Carolina</state>
        <zip>27599</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Pittsburgh</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15260</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vanderbilt-Ingram Cancer Center</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37232</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Baylor Breast Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Washington</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98195</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.vicc.org/ct/</url>
    <description>Vanderbilt-Ingram Cancer Center, Find a Clinical Trial</description>
  </link>
  <verification_date>May 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 21, 2015</study_first_submitted>
  <study_first_submitted_qc>May 26, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 29, 2015</study_first_posted>
  <last_update_submitted>May 3, 2018</last_update_submitted>
  <last_update_submitted_qc>May 3, 2018</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 10, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Vanderbilt-Ingram Cancer Center</investigator_affiliation>
    <investigator_full_name>Vandana Abramson</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
    <mesh_term>Triple Negative Breast Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Androgens</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

